Biologics for eosinophilic COPD: current applications and future prospects - PubMed
5 hours ago
- #COPD
- #eosinophilic inflammation
- #biologics
- Chronic obstructive pulmonary disease (COPD) is a heterogeneous pulmonary disorder with persistent airflow limitation and symptoms like dyspnea, cough, and sputum.
- A subset of COPD patients exhibits eosinophil-predominant type 2 inflammation, remaining at risk of exacerbations despite triple therapy.
- Monoclonal antibodies targeting IL-5/IL-5Rα, IL-4, IL-13, IL-33/ST-2, and TSLP show promise for treating eosinophilic COPD.
- Accurate and accessible biomarkers for type 2 inflammation are crucial for the development and application of these biologics.
- This review focuses on the current applications and future prospects of biologics in eosinophilic COPD, emphasizing the role of biomarkers.